Human Anti-VEGFA Recombinant Antibody (clone Bev-B5E3BsAb); scFv Fragment
On the basis of Bevacizumab and an all-human monoclonal antibody B5E3, a two-epitope bispecific antibody Bev-B5E3BsAb targeting VEGF is constructed. Experiments show that the bispecific antibody does not compete with Bevacizumab to combine with VEGF, and it is speculated that the epitopes of the bispecific antibody are new epitopes different from those of Bevacizumab. Meanwhile, compared with two parent monoclonal antibodies of the bispecific antibody, the bispecific antibody can combine with VEGF more effectively. In addition, the bispecific antibody displays stronger ability in inhibiting proliferation of human umbilical vein endothelial cells (HUVEC) in experiments in vitro; animal experiments show that the bispecific antibody can remarkably inhibit growth of tumors. Therefore, the bispecific antibody is expected to be developed into a novel antibody reagent used for treatment or diagnosis of tumors and ophthalmic diseases.
| Supplier | Creative Biolabs |
|---|---|
| Product # | HPAB-M0243-YC-S(P) |
| Pricing | Inquiry |
| Host | Human |
| Target | VEGFA |
| Species Reactivity | Human |
| Type | Humanized scFv |
| Applications | ELISA, Block, Inhib |
| Storage | Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |